Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 15.88 Mil Enterprise Value: 5.92 Mil PE Ratio: 0 PB Ratio: 0.92 GF Score: 52/100

Q3 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript

Nov 08, 2021 / 01:30PM GMT
Release Date Price: €42.75 (-6.56%)
Operator

Greetings, and welcome to Matinas BioPharma's Third Quarter 2021 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter Vozzo, Investor Relations Representative for Matinas BioPharma. Thank you. You may begin. .

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Doug. Good morning, everyone, and thank you for joining the Matinas BioPharma Third Quarter 2021 Results Conference Call. Earlier this morning, we issued a press release with our financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section. Speaking on today's call will be Jerry Jabbour, Chief Executive Officer; Dr. Terry Matkovits, Chief Development Officer; and Dr. Raphael Mannino, Chief Scientific Officer. We also have Dr. Terry Ferguson, Chief Medical Officer; and Keith Kucinski, Chief Financial Officer, available to answer questions during our Q&A session.

At this time, I would like to remind our listeners that remarks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot